The lung study promising a breath of fresh air in research worldBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6343 (Published 27 November 2015) Cite this as: BMJ 2015;351:h6343
- Matthew Limb, freelance journalist, London, UK
Researchers see it as a test bed for “real world” trials that could lead to the quicker introduction of drugs and medical devices. The Salford Lung Study is examining the safety and effectiveness of a new treatment for chronic obstructive pulmonary disease (COPD) in 80 general practices around Salford in north west England.1 About 2500 patients are participating, half randomised to a new inhalation powder Relvar Ellipta (fluticasone furoate/vilanterol) and half to usual treatment.
Conventional randomised controlled trials are usually conducted in patients with selected characteristics, an arguably artificial setting. The Salford study differs in that it is a pragmatic trial of patients from everyday general practice, the first started before licensing.2
“In a real world study the question you’re asking is, ‘Will that medicine work in the general population … and in the health service setting in which it’s provided?’” says David Leather, global medical affairs leader for sponsor GlaxoSmithKline (GSK).
“There is …